Key result
Long-term administration of low-dose rivaroxaban, in addition to standard antiplatelet therapy, is indicated for preventing cardiovascular death and myocardial infarction after acute coronary syndrome.
Why the study?
Does long-term administration of anticoagulants added to standard antiplatelet therapy prevent cardiovascular death and myocardial infarction in patients after acute coronary syndrome?
Does long-term administration of anticoagulants added to standard antiplatelet therapy prevent cardiovascular death and myocardial infarction in patients after acute coronary syndrome?
This review highlights the role of long-term anticoagulation, specifically low-dose rivaroxaban, added to standard antiplatelet therapy for secondary prevention in high-risk ACS patients.
The review tells about challenges of antithrombotic therapy in patients after acute coronary syndrome. The efficacy and safety of long-term administration of anticoagulants (warfarin as well as novel anticoagulants), in addition to standard antiplatelet therapy, is discussed. The focus is on rivaroxaban, low doses of which are officially indicated for the prevention of cardiovascular death and myocardial infarction in patients after acute coronary syndrome occurring with increased values of myocardial injury markers. Clinical characteristics of patients feasible for this treatment approach are considered .
No takes yet. Share an insight, caveat, or question.
A. L. Komarov (2016) conducted a review in Acute coronary syndrome. Anticoagulants (rivaroxaban, warfarin, novel anticoagulants) vs. Standard antiplatelet therapy was evaluated on Cardiovascular death and myocardial infarction. Long-term administration of low-dose rivaroxaban, in addition to standard antiplatelet therapy, is indicated for preventing cardiovascular death and myocardial infarction after acute coronary syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: